These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31482065)

  • 21. Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer.
    Liang YL; Lin CN; Tsai HF; Wu PY; Lin SH; Hong TM; Hsu KF
    Curr Oncol; 2021 Oct; 28(5):4234-4246. PubMed ID: 34677277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy.
    Heayn M; Skvarca LB; Zhu L; Edwards RP; Olawaiye AB; Modugno F; Elishaev E; Bhargava R
    Int J Gynecol Pathol; 2021 May; 40(3):278-285. PubMed ID: 32897953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Analysis of Prognostic Factors in Patients with Ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery.
    Yang ZJ; Liu ZC; Wei RJ; Li L
    Gynecol Obstet Invest; 2016; 81(1):1-9. PubMed ID: 25967958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
    Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
    Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
    Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score.
    McNulty M; Das A; Cohen PA; Dean A
    Int J Gynecol Cancer; 2019 May; ():. PubMed ID: 31097511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
    McIntosh LJ; O'Neill AC; Bhanusupriya S; Matalon SA; Van den Abbeele AD; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2017 Oct; 42(10):2513-2520. PubMed ID: 28429056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis.
    Wohlmuth C; Djedovic V; Kjaer SK; Jensen A; Glasspool R; Roxburgh P; DeFazio A; Johnatty SE; Webb PM; Modugno F; Lambrechts D; Schildkraut JM; Berchuck A; Thomsen LCV; Bjorge L; Høgdall E; Høgdall CK; Goode EL; Winham SJ; Matsuo K; Karlan BY; Lester J; Goodman MT; Thompson PJ; Pejovic T; Riggan MJ; Lajkosz K; Tone A; May T
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
    Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
    Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian Cancer.
    Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
    JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
    Michaan N; Chong WY; Han NY; Lim MC; Park SY
    Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.